Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NCT02236000 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT02236000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02236000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2014
Completion date
August 31, 2021
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer